94 related articles for article (PubMed ID: 1425909)
1. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.
Lu ZY; Brochier J; Wijdenes J; Brailly H; Bataille R; Klein B
Eur J Immunol; 1992 Nov; 22(11):2819-24. PubMed ID: 1425909
[TBL] [Abstract][Full Text] [Related]
2. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo.
May LT; Neta R; Moldawer LL; Kenney JS; Patel K; Sehgal PB
J Immunol; 1993 Sep; 151(6):3225-36. PubMed ID: 8376777
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
4. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes.
Finkelman FD; Madden KB; Morris SC; Holmes JM; Boiani N; Katona IM; Maliszewski CR
J Immunol; 1993 Aug; 151(3):1235-44. PubMed ID: 8393043
[TBL] [Abstract][Full Text] [Related]
5. Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes.
Martens E; Dillen C; Put W; Heremans H; van Damme J; Billiau A
Eur J Immunol; 1993 Aug; 23(8):2026-9. PubMed ID: 8344369
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
[TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological follow-up of patients with AIDS-associated Kaposi's sarcoma treated with an anti-IL-6 monoclonal antibody.
Racadot E; Audhuy B; Duvernoy H; Thyss A; Lang JM; Wijdenes J; Hervé P
Cytokines Mol Ther; 1995 Jun; 1(2):133-8. PubMed ID: 9384670
[TBL] [Abstract][Full Text] [Related]
9. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
Pallua N; Low JF; von Heimburg D
Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
[TBL] [Abstract][Full Text] [Related]
10. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
11. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments.
Lu ZY; Brailly H; Wijdenes J; Bataille R; Rossi JF; Klein B
Blood; 1995 Oct; 86(8):3123-31. PubMed ID: 7579407
[TBL] [Abstract][Full Text] [Related]
12. Blocking of interleukin 2 (IL 2) binding to the IL 2 receptor is not required for the in vivo action of anti-IL 2 receptor monoclonal antibody (mAb). I. The production, characterization and in vivo properties of a new mouse anti-rat IL 2 receptor mAb that reacts with an epitope different to the one that binds to IL 2 and the mAb ART-18.
Mouzaki A; Volk HD; Osawa H; Diamantstein T
Eur J Immunol; 1987 Mar; 17(3):335-41. PubMed ID: 3106058
[TBL] [Abstract][Full Text] [Related]
13. Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase.
Iwanami K; Matsumoto I; Tanaka-Watanabe Y; Inoue A; Mihara M; Ohsugi Y; Mamura M; Goto D; Ito S; Tsutsumi A; Kishimoto T; Sumida T
Arthritis Rheum; 2008 Mar; 58(3):754-63. PubMed ID: 18311788
[TBL] [Abstract][Full Text] [Related]
14. Immune complex-induced interleukin-6, interleukin-10 and prostaglandin secretion by human monocytes: a network of pro- and anti-inflammatory cytokines dependent on the antigen:antibody ratio.
Berger S; Balló H; Stutte HJ
Eur J Immunol; 1996 Jun; 26(6):1297-301. PubMed ID: 8647208
[TBL] [Abstract][Full Text] [Related]
15. Fas cross-linking mimics the inhibitory effect of anti-CD3 on IL-3-induced histamine and cytokine production by murine myeloid spleen cell precursors.
Ben Amor A; Schneider E; Arnould A; Machavoine F; Dy M
Exp Hematol; 1998 Aug; 26(9):903-9. PubMed ID: 9694512
[TBL] [Abstract][Full Text] [Related]
16. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody.
Ravirajan CT; Wang Y; Matis LA; Papadaki L; Griffiths MH; Latchman DS; Isenberg DA
Rheumatology (Oxford); 2004 Apr; 43(4):442-7. PubMed ID: 15024133
[TBL] [Abstract][Full Text] [Related]
17. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.
Butler DM; Maini RN; Feldmann M; Brennan FM
Eur Cytokine Netw; 1995; 6(4):225-30. PubMed ID: 8789287
[TBL] [Abstract][Full Text] [Related]
18. Binding of cytokines to pharmaceutically prepared human immunoglobulin.
Svenson M; Hansen MB; Bendtzen K
J Clin Invest; 1993 Nov; 92(5):2533-9. PubMed ID: 8227366
[TBL] [Abstract][Full Text] [Related]
19. IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis.
Suzuki H; Takemura H; Yoshizaki K; Koishihara Y; Ohsugi Y; Okano A; Akiyama Y; Tojo T; Kishimoto T; Kashiwagi H
J Immunol; 1994 Jan; 152(2):935-42. PubMed ID: 8283060
[TBL] [Abstract][Full Text] [Related]
20. Production and characterization of monoclonal antibodies to human interleukin 2: strategy and tactics.
Smith KA; Favata MF; Oroszlan S
J Immunol; 1983 Oct; 131(4):1808-15. PubMed ID: 6352804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
